1348P Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: results from two phase II studies.
Lidbrink, E Erfan, J Chmielowska, E Otremba, B Bouhlel, A Lauer, S Hermoso, M Nuesch, E Shing, M Misra, Vivek
Lidbrink, E
Erfan, J
Chmielowska, E
Otremba, B
Bouhlel, A
Lauer, S
Hermoso, M
Nuesch, E
Shing, M
Misra, Vivek
Citations
Altmetric:
Abstract
Description
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
1348P Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: results from two phase II studies. 2017, 28(suppl_5): Ann Oncol